Emily Bannister

Emily Bannister is a procurement professional specializing in scientific research and biotechnology acquisitions, playing a critical role in advancing federal R&D priorities through strategic contracting. She manages the full lifecycle of complex service contracts, from requirement development and market research to award and performance oversight, ensuring alignment with federal science and technology objectives. Her work supports mission-critical investigations in life sciences, often involving high-complexity, low-volume procurements requiring specialized technical expertise and rigorous compliance with FAR and agency-specific regulations. Bannister maintains a broad network of research-focused vendors, including academic research institutions, independent scientific laboratories, and niche biotech service providers. She frequently engages with firms capable of delivering specialized laboratory services, clinical trial support, and analytical instrumentation solutions. Her contracting patterns reflect a preference for collaborative, performance-based agreements that incentivize innovation and technical excellence, often utilizing Indefinite-Delivery, Indefinite-Quantity (IDIQ) and Other Transaction Authority (OTA) mechanisms to accelerate access to cutting-edge capabilities. Her procurement portfolio demonstrates a strong commitment to small business participation, with nearly one-fifth of her awards structured as Total Small Business Set-Asides under FAR 19.5. While the majority of her contracts are unrestricted, she consistently prioritizes opportunities for small businesses with proven scientific capabilities, particularly those with expertise in life sciences research. Her approach reflects a balanced strategy that ensures competition while fostering the growth of capable small firms in the federal science ecosystem. Bannister’s primary focus lies in NAICS 541714 (Biotechnology R&D) and 541715 (Physical, Engineering, and Life Sciences R&D), where she procures services related to drug discovery, genomic analysis, bioinformatics, and experimental laboratory research. She regularly engages contractors with specialized capabilities in molecular biology, preclinical testing, and data-driven scientific modeling, demonstrating deep domain knowledge in translational research and regulated scientific environments.